Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M P Dain

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Maturitas|November 1, 1995
Efficacy and tolerability of Menorest 50 compared with Estraderm TTS 50 in the treatment of postmenopausal symptoms. A randomized, multicenter, parallel group studyB Pornel, A R Genazzani, D Costes, et al.
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|September 29, 2014
Physical characteristics that predict final basal insulin dose in type 2 diabetes mellitus, with a special focus on BMIA C R Simon, G B Bolli, M-P Dain, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|January 22, 2013
Primary-care observational database study of the efficacy of GLP-1 receptor agonists and insulin in the UKG C Hall, A D McMahon, M-P Dain, et al.
Diabetes, Obesity & Metabolism|October 6, 2010
Continuation versus discontinuation of insulin secretagogues when initiating insulin in type 2 diabetesS G Swinnen, M-P Dain, D Mauricio, et al.
Bone|May 13, 1999
A dose-ranging trial of a matrix transdermal 17beta-estradiol for the prevention of bone loss in early postmenopausal women. International Study GroupP D Delmas, B Pornel, D Felsenberg, et al.
American Journal of Obstetrics and Gynecology|January 29, 2000
Efficacy of continuous sequential transdermal estradiol and norethindrone acetate in relieving vasomotor symptoms associated with menopauseM Notelovitz, D Cassel, D Hille, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|November 7, 1999
Matrix delivery transdermal 17beta-estradiol for the prevention of bone loss in postmenopausal women. The International Study GroupC Cooper, J A Stakkestad, S Radowicki, et al.
Diabetes, Obesity & Metabolism|December 18, 2008
Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8% A1c levels. The TULIP studyJ-F Blicklé, N Hancu, M Piletic, et al.
Clinical Drug Investigation|August 14, 2016
Bioavailability Study of Menorest®, a New Estrogen Transdermal Delivery System, Compared with a Transdermal Reservoir SystemY Le Roux, M L Borg, M Sibille, et al.
American Journal of Obstetrics and Gynecology|February 15, 2001
Three-year follow-up of the use of transdermal 17beta-estradiol matrix patches for the prevention of bone loss in early postmenopausal womenP D Delmas, B Pornel, D Felsenberg, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Maturitas|November 1, 1995
Efficacy and tolerability of Menorest 50 compared with Estraderm TTS 50 in the treatment of postmenopausal symptoms. A randomized, multicenter, parallel group studyB Pornel, A R Genazzani, D Costes, et al.
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|September 29, 2014
Physical characteristics that predict final basal insulin dose in type 2 diabetes mellitus, with a special focus on BMIA C R Simon, G B Bolli, M-P Dain, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|January 22, 2013
Primary-care observational database study of the efficacy of GLP-1 receptor agonists and insulin in the UKG C Hall, A D McMahon, M-P Dain, et al.
Diabetes, Obesity & Metabolism|October 6, 2010
Continuation versus discontinuation of insulin secretagogues when initiating insulin in type 2 diabetesS G Swinnen, M-P Dain, D Mauricio, et al.
Bone|May 13, 1999
A dose-ranging trial of a matrix transdermal 17beta-estradiol for the prevention of bone loss in early postmenopausal women. International Study GroupP D Delmas, B Pornel, D Felsenberg, et al.
American Journal of Obstetrics and Gynecology|January 29, 2000
Efficacy of continuous sequential transdermal estradiol and norethindrone acetate in relieving vasomotor symptoms associated with menopauseM Notelovitz, D Cassel, D Hille, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|November 7, 1999
Matrix delivery transdermal 17beta-estradiol for the prevention of bone loss in postmenopausal women. The International Study GroupC Cooper, J A Stakkestad, S Radowicki, et al.
Diabetes, Obesity & Metabolism|December 18, 2008
Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8% A1c levels. The TULIP studyJ-F Blicklé, N Hancu, M Piletic, et al.
Clinical Drug Investigation|August 14, 2016
Bioavailability Study of Menorest®, a New Estrogen Transdermal Delivery System, Compared with a Transdermal Reservoir SystemY Le Roux, M L Borg, M Sibille, et al.
American Journal of Obstetrics and Gynecology|February 15, 2001
Three-year follow-up of the use of transdermal 17beta-estradiol matrix patches for the prevention of bone loss in early postmenopausal womenP D Delmas, B Pornel, D Felsenberg, et al.
Pageof 3